CA2454147C - Inhibitor of dna methylation - Google Patents

Inhibitor of dna methylation Download PDF

Info

Publication number
CA2454147C
CA2454147C CA2454147A CA2454147A CA2454147C CA 2454147 C CA2454147 C CA 2454147C CA 2454147 A CA2454147 A CA 2454147A CA 2454147 A CA2454147 A CA 2454147A CA 2454147 C CA2454147 C CA 2454147C
Authority
CA
Canada
Prior art keywords
zebularine
methylation
dna
cell
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2454147A
Other languages
English (en)
French (fr)
Other versions
CA2454147A1 (en
Inventor
Eric U. Selker
Cindy B. Matsen
Sheldon B. Greer
Peter A. Jones
Jonathan Cheng
Victor E. Marquez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oregon
University of Miami
University of Southern California USC
US Department of Health and Human Services
Original Assignee
University of Oregon
University of Miami
University of Southern California USC
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oregon, University of Miami, University of Southern California USC, US Department of Health and Human Services filed Critical University of Oregon
Publication of CA2454147A1 publication Critical patent/CA2454147A1/en
Application granted granted Critical
Publication of CA2454147C publication Critical patent/CA2454147C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2454147A 2001-07-31 2002-07-30 Inhibitor of dna methylation Expired - Fee Related CA2454147C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30924201P 2001-07-31 2001-07-31
US60/309,242 2001-07-31
US31143501P 2001-08-10 2001-08-10
US60/311,435 2001-08-10
PCT/US2002/024223 WO2003012051A2 (en) 2001-07-31 2002-07-30 Inhibitor of dna methylation

Publications (2)

Publication Number Publication Date
CA2454147A1 CA2454147A1 (en) 2003-02-13
CA2454147C true CA2454147C (en) 2013-05-21

Family

ID=26976683

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2454147A Expired - Fee Related CA2454147C (en) 2001-07-31 2002-07-30 Inhibitor of dna methylation

Country Status (6)

Country Link
US (1) US8207142B2 (OSRAM)
EP (1) EP1418949B1 (OSRAM)
JP (2) JP2005508885A (OSRAM)
AU (1) AU2002322805B2 (OSRAM)
CA (1) CA2454147C (OSRAM)
WO (1) WO2003012051A2 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508885A (ja) * 2001-07-31 2005-04-07 ザ ステイト オブ オレゴン， アクティング バイ アンド スルー ザ ステイト ボード オブ ハイヤー エデュケイション オン ビハーフ オブ ザ ユニバーシティー オブ オレゴン Ｄｎａメチル化の阻害剤
US8309302B2 (en) * 2005-07-15 2012-11-13 Abbott Laboratories Reagents and methods for processing biological samples
GB0607063D0 (en) 2006-04-07 2006-05-17 Cellcentric Ltd Compositions and methods for epigenetic modification of nucleic acid sequences in vivo
JP2009278867A (ja) * 2006-09-05 2009-12-03 Olympus Corp Ｄｎａメチル化阻害作用の判定方法
EP2164500B1 (en) * 2007-05-25 2013-12-04 Idogen AB The use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
CN103517990A (zh) 2010-10-07 2014-01-15 通用医疗公司 癌症生物标志物
CA2887461A1 (en) * 2012-07-09 2014-01-16 Metheor Therapeutics Corporation Oligonucleotide inhibitors of dna methyltransferases and their use in treating diseases
CN105705150B (zh) 2013-11-14 2021-03-23 康佳诺医疗科技发展有限公司 用于癌症治疗的包含短链脂肪酸和折布拉林或1′-氰基-阿糖胞苷的互联体前药
EP3760208B1 (en) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting human satellite ii (hsatii)
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
PL241125B1 (pl) * 2017-11-30 2022-08-08 Gdanski Univ Medyczny Kompozycja farmaceutyczna do zastosowania jako środek do pobudzania regeneracji lub gojenia ran
US20210213041A1 (en) 2018-02-06 2021-07-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894364A (en) 1983-10-26 1990-01-16 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
US5470974A (en) 1985-03-15 1995-11-28 Neu-Gene Development Group Uncharged polynucleotide-binding polymers
US5607925A (en) 1988-11-15 1997-03-04 Merrell Pharmaceuticals Inc. Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides
US5503975A (en) 1989-03-01 1996-04-02 City Of Hope Mechanism based inhibitors of DNA methyltransferase
EP0586523A4 (en) 1991-05-15 1995-11-29 Univ Yale Determination of prodrugs metabolizable by the liver and therapeutic use thereof
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
EP0889122A3 (en) 1993-11-30 1999-03-03 McGILL UNIVERSITY Inhibition of DNA Methyltransferase
CA2153125A1 (en) * 1994-08-31 1996-03-01 Frank Paul Abuto Liquid-absorbing article
US5872104A (en) 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
US6020139A (en) 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5871917A (en) 1996-05-31 1999-02-16 North Shore University Hospital Research Corp. Identification of differentially methylated and mutated nucleic acids
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6011200A (en) 1997-07-30 2000-01-04 Yale University Methods for altering the rate of plant development and plants obtained therefrom
WO1998056952A1 (en) 1997-06-09 1998-12-17 University Of Southern California A cancer diagnostic method based upon dna methylation differences
DE19754482A1 (de) 1997-11-27 1999-07-01 Epigenomics Gmbh Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke
AU5128999A (en) 1998-07-24 2000-02-14 Yeda Research And Development Co. Ltd. Prevention of metastasis with 5-aza-2'-deoxycytidine
AU3354500A (en) 1999-03-01 2000-09-21 Halogenetics, Inc. Dramatic simplification of a method to treat neoplastic disease by radiation
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
JP2005508885A (ja) * 2001-07-31 2005-04-07 ザ ステイト オブ オレゴン， アクティング バイ アンド スルー ザ ステイト ボード オブ ハイヤー エデュケイション オン ビハーフ オブ ザ ユニバーシティー オブ オレゴン Ｄｎａメチル化の阻害剤
EP1718150A1 (en) 2004-02-25 2006-11-08 The Government of the United States of America, represented by the Secretary, Department of Health and Human Services Methylation inhibitor compounds

Also Published As

Publication number Publication date
EP1418949A4 (en) 2009-03-04
JP5416660B2 (ja) 2014-02-12
WO2003012051A8 (en) 2003-08-14
WO2003012051A3 (en) 2003-10-30
EP1418949A2 (en) 2004-05-19
US20050119201A1 (en) 2005-06-02
JP2005508885A (ja) 2005-04-07
AU2002322805B2 (en) 2007-11-08
CA2454147A1 (en) 2003-02-13
WO2003012051A2 (en) 2003-02-13
US8207142B2 (en) 2012-06-26
JP2010248223A (ja) 2010-11-04
AU2002322805A2 (en) 2003-02-17
EP1418949B1 (en) 2013-06-19

Similar Documents

Publication Publication Date Title
JP5416660B2 (ja) Ｄｎａメチル化の阻害剤
Gowher et al. Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy
Cheng et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine
JP7558963B2 (ja) 修飾されたマイクロｒｎａ及びがんの処置におけるその使用
Glover et al. Biochemistry of Azacitidine: A Review¹
AU2002322805A1 (en) Inhibitor of DNA methylation
K. Li et al. DNA methylation as a target of epigenetic therapeutics in cancer
AU728377C (en) Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
CN112566628A (zh) 预防和治疗癌症的药物组合物，包括棉酚、苯乙双胍和抗癌剂
AU2008200601B2 (en) Inhibitor of DNA Methylation
WO2008054767A2 (en) N4 modifications of pyrimidine analogs and uses thereof
WO2019108072A1 (en) Use of zebularine for promoting wound healing and regeneration
JP7707184B2 (ja) 修飾短干渉ｒｎａ組成物、及びがんの処置におけるそれらの使用
Kirsanova et al. Inhibition of C5-cytosine-DNA-methyltransferases
EP2869852A2 (en) Oligonucleotide inhibitors of dna methyltransferases and their use in treating diseases
Roatsch et al. DNA-modifying Enzymes
Bruzzese et al. Targeting the Menin–KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation
CA2149626A1 (en) Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers which comprise pyrimidine analogs
HU201678B (en) Process for producing pharmaceutical compositions against human retrovirus, comprising 3'-azido-3'-deoxythymide derivatives
Cheng Characterization of zebularine: A novel inhibitor of DNA methylation with clinical potential
Bojang et al. Epigenetic Therapies for Cancer
Abid Epigenetic therapy in cancer
Lübbert et al. 14 DNA Demethylating Agents: Clinical Uses
HK40049617A (en) Pharmaceutical composition for preventing or treating cancer, comprising gossypol, phenformin, and anticancer agent
Atallah et al. Epigenetic Drugs: DNA Demethylating Agents

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200831